About AVT
Browse Articles
Customer Services

Current Issue

Displaying 15 results:


Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients

Adele L McCormick, Luke Moynihan, Malcolm J Macartney, Ana Garcia-Diaz, Colette Smith, Margaret A Johnson, Alison J Rodger, Sanjay Bhagani, Tanzina Haque, Daniel P Webster

Antiviral Therapy 2015; 20:361-363

Case report

Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS

Alice Trentalange, Andrea Calcagno, Stefania Raviolo, Adolfo Prochet, Sabrina Audagnotto, Valeria Ghisetti, Giovanni Di Perri, Stefano Bonora

Antiviral Therapy 2015; 20:357-359

Case report

Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV–HCV-coinfected patient

Patrick Borentain, Philippe Colson, Catherine Dhiver, Emilie Gregoire, Jean Hardwigsen, Danielle Botta-Fridlund, Stéphane Garcia, René Gerolami

Antiviral Therapy 2015; 20:353-356

Case report

The reactivation of occult HBV infection emerging with the case of acute hepatitis B in the wife of a subject treated with rituximab-based chemotherapy

Margherita Macera, Nicolina Capoluongo, Michele Gambardella, Mario Starace, Carmine Minichini, Mariantonietta Pisaturo, Giuseppe Pasquale, Nicola Coppola

Antiviral Therapy 2015; 20:349-352

Short communication

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

Bisher Akil, Gary Blick, Debbie P Hagins, Moti N Ramgopal, Gary J Richmond, Rafik M Samuel, Naomi Givens, Cindy Vavro, Ivy H Song, Brian Wynne, Mounir Ait-Khaled, the VIKING-4 study team

Antiviral Therapy 2015; 20:343-348

Short communication

Vitamin D pathway gene variants and HCV-2/3 therapy outcomes

Jessica Cusato, Sarah Allegra, Lucio Boglione, Amedeo De Nicolò, Lorena Baietto, Giuseppe Cariti, Giovanni Di Perri, Antonio D’Avolio

Antiviral Therapy 2015; 20:335-341

Original article

Liver fibrosis progression despite HCV cure with antiviral therapy in HIV–HCV-coinfected patients

Pablo Labarga, Jose V Fernandez-Montero, Carmen de Mendoza, Pablo Barreiro, Javier Pinilla, Vincent Soriano

Antiviral Therapy 2015; 20:329-334

Original article

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients

Kirsten L White, Rima Kulkarni, Damian J McColl, Martin S Rhee, Javier Szwarcberg, Andrew K Cheng, Michael D Miller

Antiviral Therapy 2015; 20:317-327

Original article

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection

Joseph J Eron, David A Cooper, Roy T Steigbigel, Bonaventura Clotet, Patrick Yeni, Kim M Strohmaier, Anthony J Rodgers, Richard J Barnard, Bach-Yen T Nguyen, Hedy Teppler, the BENCHMRK Study Teams

Antiviral Therapy 2015; 20:307-315

Original article

Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment

Tanuja N Gengiah, Julia H Botha, Nonhlanhla Yende-Zuma, Kogieleum Naidoo, Salim S Abdool Karim

Antiviral Therapy 2015; 20:297-306

Copyright © Nucleus Global 2015. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.